MB
Akebia Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Vadadustat | Anemia due to CKD in adult patients on dialysis | Approved |
| Auryxia (ferric citrate) | Hyperphosphatemia in CKD patients on dialysis; Iron deficiency anemia in CKD patients not on dialysis | Approved |
| HIF-PHI Platform | Other potential renal/metabolic disorders | Research |
Leadership Team at Akebia Therapeutics
JB
John Butler
President and Chief Executive Officer
SK
Steven K. Burke, M.D.
Senior Vice President, Chief Research & Development Officer
NG
Nicholas Grund
Senior Vice President, Chief Commercial Officer
JM
Justin McCue, Ph.D.
Senior Vice President, Chief Technology Officer
EO
Erik Ostrowski
Senior Vice President, Chief Financial Officer and Chief Business Officer
CR
Carolyn Rucci
Senior Vice President, Chief Legal Officer & Secretary
AA
Adrian Adams
Chairperson of the Board of Directors